HilleVax (NASDAQ:HLVX – Get Free Report) and Compass Therapeutics (NASDAQ:CMPX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.
Volatility & Risk
HilleVax has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.
Institutional and Insider Ownership
86.4% of HilleVax shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 29.3% of HilleVax shares are held by insiders. Comparatively, 30.0% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| HilleVax | N/A | N/A | -$123.57 million | ($3.04) | -4.21 |
| Compass Therapeutics | N/A | N/A | -$42.49 million | ($0.34) | -4.26 |
Compass Therapeutics is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares HilleVax and Compass Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| HilleVax | N/A | -48.17% | -38.05% |
| Compass Therapeutics | N/A | -26.07% | -24.49% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for HilleVax and Compass Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| HilleVax | 0 | 0 | 3 | 0 | 3.00 |
| Compass Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
HilleVax presently has a consensus target price of $30.67, suggesting a potential upside of 139.77%. Compass Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 520.69%. Given Compass Therapeutics’ higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than HilleVax.
Summary
Compass Therapeutics beats HilleVax on 7 of the 10 factors compared between the two stocks.
About HilleVax
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.
